Oncimmune
Founded in 2006, Oncimmune specializes in early cancer detection using proprietary autoantibody assay technologies. Headquartered in Nottingham, England, with a CLIA-certified lab in Kansas City, the company aims to detect over 90% of solid-tumor cancers through its tests for lung, breast, colorectal, prostate, stomach, pancreatic, and ovarian cancers.
Top Stages
1 past transactions
Protagen
Acquisition in 2019
Protagen is a precision medicine company that specializes in drug development and patient management, particularly in the fields of autoimmune diseases and immuno-oncology. The company focuses on immuno-profiling and the discovery of novel autoantibody signatures, utilizing its SeroTag® technology to identify biomarkers that address challenges in the development of cancer immunotherapies and treatments for autoimmune conditions. Protagen is recognized for its expertise in patient stratification, having created disease-specific NavigAID panels that assess individual patients' autoimmune conditions and immune statuses. This tailored approach enables the development of more targeted therapies for various autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and Sjögren’s syndrome. Additionally, Protagen's biomarker discovery platform aids in the detection of autoantibodies in patients undergoing cancer immunotherapy, which helps predict treatment responses and supports informed therapeutic decisions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.